RA CAPITAL MANAGEMENT, L.P. - 22 Jul 2021 Form 3 Insider Report for Cytek BioSciences, Inc. (CTKB)

Role
Director
Signature
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
Issuer symbol
CTKB
Transactions as of
22 Jul 2021
Net transactions value
$0
Form type
3
Filing time
22 Jul 2021, 21:24:22 UTC
Previous filing
08 Jul 2021
Next filing
29 Jul 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CTKB Series D Preferred Stock 22 Jul 2021 Common Stock 5,150,751 See footnotes F1, F2, F3
holding CTKB Series D Preferred Stock 22 Jul 2021 Common Stock 998,553 See footnote F1, F3, F4
holding CTKB Series D Preferred Stock 22 Jul 2021 Common Stock 507,724 See footnote F1, F3, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each share of Series D Preferred Stock will automatically convert into one share of Common Stock of the Issuer upon the closing of the Issuer's initial public offering. The Series D Preferred Stock has no expiration date.
F2 Shares held directly by RA Capital Healthcare Fund, L.P. (the "Fund").
F3 RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
F4 Shares held directly by the Nexus Fund II.
F5 Shares held directly by the Account.